Description

ABSTRACT

Introduction: Prescription drugs have been an issue that various organizations tried to examine for the years. A few endeavors have been made toward facilitating the burden of drug costs for the nationals. While a great part of the exchange has concentrated on the effect on Medicare and Medicaid, the scan for the wellspring of high physician recommended medicates costs has conceivable advantages for all patients. Present work was done with an intention to investigate the relationship between high cost of prescription drugs and its regulations across regulated and less regulated markets and to discover new modules to lowered down the costs so that the policy makers intends to think for a change. Methodology: Anti-diabetic and anti-hypertensive drugs for cost analysis based on pricing regulations in India and USA are selected. The cost analysis of drugs are based on the queering out various data bases of both pharmaceutical market i.e. India and USA along with number of manufacturers, dose of drug, patented drugs, their generic alternates, dose combinations price variation within country between different manufacturers and other factors etc. Result: The results of the study reveal the need of extensive research. In addition, the normal cost obviously isn’t an exact reason for examination. The drug manufacturers in markets like USA should not be provided monopoly rights for a longer period and the efforts should be made towards easing the process of generic drug approval for its availability in the market for lower down the price of the medicine (drug). Conclusion: The study makes the prescriber and people aware about various types of antidiabetics and anti-hypertensive drugs available throughout the world with their difference in prices in regulated and less regulated markets. This variation in the prices can be reduced by regulating the areas and pharmaceutical companies who actually don’t follow it.

Keywords: Anti-hypertensive, Anti-diabetic pricing regulation, Prescription drugs